957793-36-1

Basic information

• Product Name: trans-3-Aminocyclobutanecarboxylic acid ethyl ester hydrochloride
• Synonyms: trans-3-Aminocyclobutanecarboxylic acid ethyl ester hydrochloride
• CAS NO: 957793-36-1
• Molecular Formula: C₇H₁₃NO₂*ClH
• Molecular Weight: 179.646
• Mol File: 957793-36-1.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: trans-3-Aminocyclobutanecarboxylic acid ethyl ester hydrochloride(CAS DataBase Reference)
• NIST Chemistry Reference: trans-3-Aminocyclobutanecarboxylic acid ethyl ester hydrochloride(957793-36-1)
• EPA Substance Registry System: trans-3-Aminocyclobutanecarboxylic acid ethyl ester hydrochloride(957793-36-1)

Safety Data

• Hazardous Substances Data: 957793-36-1(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Research and Development:
Trans-3-aminocyclobutanecarboxylic acid ethyl ester hydrochloride is utilized as a key intermediate in the synthesis of various pharmaceuticals, contributing to the development of new drugs and therapeutic agents.
Used in the Production of Fine Chemicals:
trans-3-Aminocyclobutanecarboxylic acid ethyl ester hydrochloride is employed as an intermediate in the production of fine chemicals, which are high-purity chemicals used in various applications, including the fragrance, flavor, and specialty chemical industries.
Used in Organic Compound Synthesis:
Trans-3-aminocyclobutanecarboxylic acid ethyl ester hydrochloride is used as a building block in the synthesis of other organic compounds, facilitating the creation of complex molecules for a range of applications.
It is essential to handle and store trans-3-aminocyclobutanecarboxylic acid ethyl ester hydrochloride with appropriate safety measures due to its potentially hazardous nature.

InChI:InChI=1/C7H13NO2.ClH/c1-2-10-7(9)5-3-6(8)4-5;/h5-6H,2-4,8H2,1H3;1H/t5-,6-;

Upstream product

• 87121-89-9 ethyl 3-oxocyclobutanecarboxylate 
• 23761-23-1 3-oxocyclobutanecarboxylic acid 
• 160351-97-3 ethyl (1S,3S)-3-hydroxycyclobutane-1-carboxylate 
• 64-17-5 ethanol 
• 84182-60-5 hydrochloride of trans-3-aminocyclobutane-1-carboxylic acid 

Relevant articles and documents

ISOXAZOLE DERIVATIVES FOR USE IN THE TREATMENT OF PULMONARY DISEASES AND DISORDERS

The present disclosure features disclosed method of treating disorders such as COPD, bronchitis and/or asthma using disclosed compounds, optionally together with one or more additional active agents. Contemplated methods include administrating orally or by inhalation to a patient one or more disclosed compounds.

Novel indazoles for the treatment and prophylaxis of respiratory syncytial virus infection

The invention provides novel compounds having the general formula: wherein R1, R2, R3, R4, R5, R7, A1, A2 and A3 are as described herein, compositions including the compounds and methods of using the compounds.

COMPOUNDS, COMPOSITIONS AND METHODS FOR INCREASING CFTR ACTIVITY

The present disclosure features compounds such as those having the Formulae (Ila), (lIb), (lIc), (Ild), (IlIa), and (Illb), which can increase cystic fibrosis transmembrane conductance regulator (CFTR) activity as measured in human bronchial epithelial (hBE) cells. The present disclosure also features methods of treating a condition associated with decreased CFTR activity or a condition associated with a dysfunction of proteostasis comprising administering to a subject an effective amount of a disclosed compound, such as a compound of Formula (Ila), (lIb), (lIc), (lId), (IlIa), or (Illb).

Novel indazoles for the treatment and prophylaxis of respiratory syncytial virus infection

The invention provides novel compounds having the general formula: wherein R1, R2, R3, R4, R5, R7, A1, A2 and A3 are as described herein, compositions including the compounds and methods of using the compounds.

CYCLOBUTYL CARBOXYLIC ACID DERIVATIVES

The invention relates to compounds of formula (I) and to pharmaceutically acceptable salts, prodrugs, solvates or hydrates thereof. This invention also relates to a method of using such compounds in the treatment of hyperproliferative diseases and autoimm